))
Clinical Trial at MMC Gives Hope to Patients with Brain Tumor
Series guardadas ("Feed inactivo" status)
When?
This feed was archived on July 10, 2023 20:58 (
Why? Feed inactivo status. Nuestros servidores no pudieron recuperar un podcast válido durante un período sostenido.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 167622411 series 1166293
Contenido proporcionado por info@radiomd.com and MMC Radio. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente info@radiomd.com and MMC Radio o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Recurrent brain cancer, called glioblastoma multiforme (GBM) can be a life threatening condition, however, immunotherapy – which is showing tremendous promise for many cancers – is now being tested against this cancer. The trial is testing a vaccine created with the patient's own tumor tissue.Immunotherapies are treatments that restore or enhance the immune system’s natural ability to fight cancer. In just the past few years, cancer immunology has produced several new methods of treating cancer that increase the strength of immune responses against tumors.
Maine Medical Center is participating in this phase II randomized trial through its participation in the Alliance for Clinical Trials in Oncology.
Listen in as Christine Lu-Emerson, M.D discusses how the clinical trial at MMC gives hope to patients diagnosed with a brain tumor.
76 episodios
Compartir
